Last $110.90 USD
Change Today +0.82 / 0.74%
Volume 198.7K
TFX On Other Exchanges
New York
As of 8:04 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

teleflex inc (TFX) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/24/14 - $111.56
52 Week Low
10/25/13 - $86.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TELEFLEX INC (TFX)

Related News

No related news articles were found.

teleflex inc (TFX) Related Businessweek News

No Related Businessweek News Found

teleflex inc (TFX) Details

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company operates in three segments: Vascular, Anesthesia/Respiratory, and Surgical. It offers vascular access products that facilitate various critical care therapies, including the administration of intravenous medications and other therapies, the measurement of blood pressure, and taking of blood samples through a single puncture site; anesthesia products, such as airway management products under the LMA and Rusch brands, and pain management products under the Arrow brand; respiratory care products, such as oxygen therapy, aerosol therapy, spirometry, and ventilation management products under the Hudson RCI brand; and specialty products, including interventional access products, and products provided to specialty market customers. The company also provides surgical products, such as ligation and closure products used in surgical procedures; access ports for use in minimally invasive surgical procedures; fluid management products for use in chest drainage; and reusable hand-held instruments for general and specialty surgical procedures under the Deknatel, Pilling, Pleur-evac, Taut, and Weck brands. In addition, it offers cardiac care products comprising diagnostic catheters, including thermodilution and wedge pressure catheters; angiographic and therapeutic delivery catheters; sheaths for femoral and trans-radial aortic access, and intra-aortic balloons; and capital equipment, such as intra-aortic balloon pumps under the Arrow brand. Further, the company provides original equipment manufacturing and development services. Teleflex Incorporated offers its products to hospitals and healthcare providers in approximately 150 countries through its direct sales force and distributors. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.

11,400 Employees
Last Reported Date: 02/24/14
Founded in 1943

teleflex inc (TFX) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $826.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $441.5K
Executive Vice President and President of Ame...
Total Annual Compensation: $427.1K
Compensation as of Fiscal Year 2013.

teleflex inc (TFX) Key Developments

Teleflex Incorporated Announces Voluntary Recall of Hudson RCI(R) Pediatric Anesthesia Breathing Circuits

Teleflex Incorporated announced that the U.S. Food and Drug Administration (FDA) has classified the voluntary medical device recall of Hudson RCI(R) Pediatric Anesthesia Breathing Circuits as a Class 1 recall. FDA defines Class I recalls as, "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death." Teleflex is recalling the products due to receipt of complaints that the ends of the pediatric breathing circuits can crack prior to and during use. If the circuits crack during use, there will be a need for immediate replacement of the device, and possible respiratory distress to the patient. Teleflex notified both domestic and foreign hospitals and distributors via an Urgent Medical Device recall letter dated September 10, 2014. This recall involves the retrieval of unused product in the field. Six product codes 313901, 353900, 353901, 353911, 353911, and 353811 over thirty lots 02F1300085, 02E1300623, 02F1300101, 02D1300854, 02F1300098, 02E1301891, 02E1300618, 02H1300172, 02G1300879, 02G1300296, 02H1300454, 02F1300177, 02G1300861, 02H1301128, 02J1300876, 02F1300729, 02F1300180, 02H1301838, 02G1300088, 02E1301378, 02E1301383, 02E1300090, 02E1301892, 02J1302412, 02F1300102, 02F1300100, 02E1301867, 02F1302029, 02F1302047, 02B1400324 are affected by this recall for a total of 27,176 units distributed to the field.

Teleflex Incorporated Announces Results of New Peer-Reviewed Study Involving the ARROW PICC with Chlorag ard Technology

Teleflex Incorporated has announced results of a new peer-reviewed study involving the ARROW(R) PICC with Chlorag(+) ard(R) Technology, published in the Fall 2014 issue of the Journal of the Association for Vascular Access (JAVA). The ARROW(R) PICC with Chlorag(+) ard(R) Technology is the world's first and only antimicrobial and antithrombogenic PICC. The research, using the ARROW(R) PICC with Chlorag(+) ard(R) Technology, determined that this kind of Peripherally Inserted Central Catheter (PICC) was associated with a nearly nine-fold drop in the rate of Central Line-Associated Bloodstream Infections (CLABSIs). The peer-reviewed study was conducted at Sharp Chula Vista Medical Center (SCVMC) in Chula Vista, Calif. The study was undertaken in part because the medical center's CLABSI rate had remained above the national benchmark, despite comprehensive efforts to prevent these potentially deadly infections. Use of an antimicrobial catheter in such circumstances is recommended by the CDC and the Infusion Nurses Society. In the study, concurrent data was collected from 260 patients who received the ARROW(R) PICC with Chlorag(+) ard(R) Technology. That data was then compared to retrospective data for 257 patients who had only received unprotected PICCs during the previous year. The results of the study showed a clear, positive impact from the ARROW(R) PICC with Chlorag(+) ard(R) Technology. The 257 subjects in the non-interventional group had eight CLABSIs and an infection rate of 4.18/1,000 line days. The 260 subjects in the interventional group had only one CLABSI and an infection rate of 0.47 infections/1,000 line days. In addition, a financial analysis showed that the ARROW(R) PICC with Chlorag(+) ard(R) Technology reduced costs associated with CLABSIs. Using the device enabled the hospital to avoid seven CLABSIs during the six-month study period. Conservatively assuming a treatment cost of $16,500 per infection, researchers calculated that SCVMC saved $115,500 during the study period -- an amount that includes the added cost for the preventive PICCs. The study author was Glenell Rutkoff, MSN, RN, CGRN, Manager Ambulatory and Ancillary Services at SCVMC.

Teleflex Incorporated Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 10:00 AM

Teleflex Incorporated Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 10:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Benson F. Smith, Chairman, Chief Executive Officer, President and Member of Non-Executive Equity Awards Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TFX:US $110.90 USD +0.82

TFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ansell Ltd A$19.55 AUD +0.26
Hill-Rom Holdings Inc $43.62 USD +0.04
PerkinElmer Inc $41.72 USD +0.59
Sirona Dental Systems Inc $78.54 USD +0.38
STERIS Corp $59.60 USD -0.75
View Industry Companies

Industry Analysis


Industry Average

Valuation TFX Industry Range
Price/Earnings 30.3x
Price/Sales 2.6x
Price/Book 2.3x
Price/Cash Flow 27.9x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TELEFLEX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at